EcoDrugPlus

Lysyl Oxidase-Like 2a

Ensembl ID : ENSOJAG00000009638
Gene Symbol: LOXL2A
1 Cross references
209 Possible Orthologues:

Lysyl Oxidase-Like 2b

Ensembl ID : ENSOJAG00000022058
Gene Symbol: LOXL2B
1 Cross references
210 Possible Orthologues:

Macrophage Migration Inhibitory Factor

Ensembl ID : ENSOJAG00000012387
Gene Symbol: MIF
1 Cross references
229 Possible Orthologues:

Macrophage Stimulating 1 Receptor

Ensembl ID : ENSOJAG00000000877
Gene Symbol: MST1R
1 Cross references
188 Possible Orthologues:

Matrix Metallopeptidase 13a

Ensembl ID : ENSOJAG00000008370
Gene Symbol: MMP13A
1 Cross references
283 Possible Orthologues:

Matrix Metallopeptidase 14a (Membrane-Inserted)

Ensembl ID : ENSOJAG00000004232
Gene Symbol: MMP14A
1 Cross references
198 Possible Orthologues:

Matrix Metallopeptidase 14b (Membrane-Inserted)

Ensembl ID : ENSOJAG00000008770
Gene Symbol: MMP14B
1 Cross references
196 Possible Orthologues:

Matrix Metallopeptidase 2

Ensembl ID : ENSOJAG00000001420
Gene Symbol: MMP2
1 Cross references
209 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSOJAG00000010824
Gene Symbol: MMP9
1 Cross references
215 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSOJAG00000009037
Gene Symbol: MC1R
1 Cross references
159 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSOJAG00000021118
Gene Symbol: MC4R
1 Cross references
89 Possible Orthologues:

Melatonin Receptor 1a A

Ensembl ID : ENSOJAG00000010642
Gene Symbol: MTNR1AA
1 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).